Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Paxman AB is a Swedish-based company specializing in the manufacturing and distribution of medical devices, primarily focusing on scalp cooling systems designed to reduce chemotherapy-induced hair loss. The company's innovative scalp cooling technology is renowned for its efficacy in minimizing hair loss associated with cancer treatments, serving as a vital supportive care option for patients undergoing chemotherapy. Paxman AB's products are utilized in hospitals and cancer treatment centers across numerous countries, highlighting its significant impact on the healthcare sector. With a strong emphasis on research and development, the company strives to enhance its product offerings and expand its market presence. Paxman AB plays a crucial role in oncology supportive care, contributing to improving the quality of life for cancer patients worldwide through effective non-pharmaceutical interventions.
kr 4.37
+kr 0.00 (+0.11%)
EOD Jun 25, 2026 · Twelve Data
Operating margin is thin at 1.36%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 23.8%, still solid. Margins contracted 11.9pp, which offsets some of the top-line progress.
Free cash flow declined 204% versus the prior year, cash generation momentum has weakened. ROIC dropped from 20.64% to 1.13%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 336M
▲ +23.8% YoY
Net Income (TTM)
-kr 11M
▼ -141.6% YoY
Op. Margin
-0.39%
▼ -11.9pp YoY
ROIC
1.13%
▼ -19.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 23M
▼ -204.5% YoY
Op. Cash Flow (TTM)
-kr 11M
▼ -101.8% YoY
Net Debt
-kr 108M
Net Cash Position
Cash & Equiv.
kr 121M
3Y CAGR: +29.0%
Continue Research
Paxman AB (PAX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Paxman AB scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Paxman AB scores 36 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -0.4% operating margin and a 1.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PAX.XSTO's valuation and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.